What makes our QPPV Services Unique?
Tuesday, 22 March 2022

A Qualified Person for Pharmacovigilance (QPPV) is personally responsible, by law, for the safety of the human pharmaceutical products marketed by that company in the EU.

Continue Reading
Why Foundations’ Disease Registries are important and how they are different from Clinical trials
Tuesday, 15 March 2022

Registries are a carefully curated database of people with a specific disease, it is observational and retrospective.

Continue Reading
Identifying Gaps in Diagnosis and Management of Glaucoma for Glaucoma Awareness Week
Tuesday, 08 March 2022

World Glaucoma Week is celebrated March 6-12th 2022 to raise awareness about glaucoma and the need for early diagnosis. It is the leading cause of irreversible blindness worldwide,

Continue Reading
How Navitas Life Sciences Supports Efficient Total and Transferrin bound Iron assay for Iron Sucrose formulations
Monday, 28 February 2022

Iron has an important role in certain cellular metabolic pathways and is also vital for heme synthesis and in the transport of oxygen.

Continue Reading
6 Characteristics that Define Navitas Clinical Research’s Therapeutic and Disease Specific Foundation Registry Effort
Monday, 21 February 2022

Navitas Clinical Research, a part of Navitas Life Sciences Ltd, is a full-service CRO supporting diverse clients with the design, execution,

Continue Reading
How Navitas Life Sciences is attracting more women to pursue a career in supporting Global Public Health
Monday, 14 February 2022

As a Clinical Research Organization (CRO), Navitas Life Sciences has been taking profound steps to support better care and treatment for patients with wide ranging illnesses.

Continue Reading
An Insight into Oncology Clinical Trials at Navitas Life Sciences
Tuesday, 08 February 2022

It was World Cancer Day on 4th February 2022, and our latest blog highlights our successful management of oncology clinical trials.

Continue Reading
Top 5 On-Demand Webinars that you should not miss from 2021
Wednesday, 02 February 2022

Navitas Life Sciences has access to cutting edge perspective owing to vast experience, and a pulse on the latest in the industry.

Continue Reading
How we Effectively Manage Our Glaucoma Clinical Trials
Tuesday, 25 January 2022

January is Glaucoma Awareness Month and we would like to highlight the significance of glaucoma research to support people with glaucoma.

Continue Reading
A closer look at the USFDA Review of Our Generics Studies
Tuesday, 18 January 2022

A report by globalnewswire highlights the growing market for generics, with the generic drugs market in 2020 valued at US$ 390.57 billion expected to cross US$ 574.63 billion by 2030,

Continue Reading